Cinctive Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $681K | Sell |
18,731
-58,530
| -76% | -$2.13M | 0.04% | 285 |
|
|
2025
Q1 | $2.8M | Buy |
77,261
+14,301
| +23% | +$518K | 0.21% | 133 |
|
|
2024
Q4 | $2.65M | Buy |
62,960
+47,058
| +296% | +$1.98M | 0.13% | 186 |
|
|
2024
Q3 | $883K | Sell |
15,902
-110,779
| -87% | -$6.15M | 0.05% | 285 |
|
|
2024
Q2 | $5.21M | Buy |
126,681
+14,930
| +13% | +$614K | 0.25% | 125 |
|
|
2024
Q1 | $5.22M | Buy |
111,751
+13,700
| +14% | +$640K | 0.24% | 119 |
|
|
2023
Q4 | $4.69M | Buy |
+98,051
| New | +$4.69M | 0.31% | 102 |
|
|
2022
Q2 | – | Sell |
-89,692
| Closed | -$6.51M | – | 576 |
|
|
2022
Q1 | $6.51M | Buy |
89,692
+15,936
| +22% | +$1.16M | 0.24% | 120 |
|
|
2021
Q4 | $6.2M | Buy |
73,756
+14,927
| +25% | +$1.26M | 0.27% | 111 |
|
|
2021
Q3 | $5.31M | Buy |
58,829
+30,118
| +105% | +$2.72M | 0.26% | 112 |
|
|
2021
Q2 | $2.74M | Buy |
28,711
+13,756
| +92% | +$1.31M | 0.13% | 227 |
|
|
2021
Q1 | $1.7M | Buy |
14,955
+9,008
| +151% | +$1.03M | 0.1% | 277 |
|
|
2020
Q4 | $823K | Sell |
5,947
-28,102
| -83% | -$3.89M | 0.07% | 279 |
|
|
2020
Q3 | $2.8M | Sell |
34,049
-4,059
| -11% | -$334K | 0.25% | 158 |
|
|
2020
Q2 | $2.98M | Sell |
38,108
-21,925
| -37% | -$1.72M | 0.34% | 118 |
|
|
2020
Q1 | $2.67M | Sell |
60,033
-73,568
| -55% | -$3.27M | 0.59% | 61 |
|
|
2019
Q4 | $5.71M | Buy |
+133,601
| New | +$5.71M | 0.6% | 72 |
|